ACCESSIBILITY

24/7

Headlines

20:46

Families of October 7 victims file $1 billion lawsuit against Meta over role in Hamas atrocity videos

20:02

SentinelOne buys two-year-old GenAI cyber startup Prompt for $250M

16:15

Full list of Israeli high-tech funding rounds in 2025

16:00

QuamCore raises $26 million Series A to break quantum’s scalability wall

Buzz

Most popular

Daily

Weekly

Shlomo Kramer: “The Palo Alto-CyberArk acquisition is the end of a successful run from PANW”

Vast Data nears record-breaking round as Israel’s quiet AI star targets $30 billion valuation

SentinelOne buys two-year-old GenAI cyber startup Prompt for $250M

Palo Alto closing on over $20 billion acquisition of CyberArk

Palo Alto CEO on $25B CyberArk deal: “This is the lowest our stock will be for the next five years”

More news

Biomed

9 stories about Biomed

Fourth Time’s the Charm for Entera Bio IPO

01.07.18|Dror Reich

The Israel-based oral drug developer listed on Nasdaq on Thursday, pricing 1.4 million units of one share and one warrant at $8 each

Entera Bio Gives Nasdaq IPO Another Shot

21.05.18|Dror Reich

This is the fourth time since 2014 that the Jerusalem-based biomed company files for an initial public offering on Nasdaq

Pharma Company Opko Health Retracts Decision to Delist From the Tel Aviv Stock Exchange

29.04.18|Racheli Bindman

Dually listed on Nasdaq and TASE, Opko first submitted a request to delist from the TASE in early April

An Israeli Company Wants to Treat Tourette Syndrome With Cannabis

09.04.18|Lilach Baumer

Therapix Biosciences announced the successful completion of phase 2 clinical trial of its cannabinoid-based drug, conducted at Yale University Monday

For the Fourth Time, Entera Bio Tries for Nasdaq IPO

08.01.18|Dror Reich

The Jerusalem-based biomed company plans to raise $55 million, with Oppenheimer & Co. as the sole underwriter

Biomed Company Protalix to Lay Off a Fifth of its Workforce

26.11.17|Dror Reich

The Israel-based NYSE American-listed company is currently undergoing a streamlining process

Entera Bio Files for Nasdaq IPO

12.11.17|Lilach Baumer

The clinical stage company develops treatments mostly for osteoporosis and bone disorders

Collplant Takes a Step Towards 3D Organ Printing

17.10.17|Lilach Baumer

The Israel-based company develops collagen-based biological ink for 3D organ printing

IPO Hopeful Entera Bio Moves to Better Position

13.09.17|Dror Reich

Clinical-stage company Entera Bio develops pioneering technology for orphan disease hypoparathyroidism